Single administration of intracameral bimatoprost implant: IOP lowering, safety

Video
Conference|AAO

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

See more AAO coverage here

Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
Related Content
Study: Virus that causes COVID-19 can penetrate blood-retinal barrier and may damage vision

Study: Virus that causes COVID-19 can penetrate blood-retinal barrier and may damage vision

May 15th 2024
Article
Integrating AI to manage DR in a primary care setting

Integrating AI to manage DR in a primary care setting

December 1st 2020
Podcast
Visual recovery in open-globe injuries with NLP vision cannot be predicted based on clinical features

Visual recovery in open-globe injuries with NLP vision cannot be predicted based on clinical features

May 6th 2024
Article
What to expect from virtual AAO 2020

What to expect from virtual AAO 2020

November 5th 2020
Podcast
A wireless visual prosthesis stimulates neurons to produce a new form of artificial sight

A wireless visual prosthesis stimulates neurons to produce a new form of artificial sight

April 16th 2024
Article
Nfe2l3: A neuroprotectant and possible therapeutic target for CNS injury/disease

Nfe2l3: A neuroprotectant and possible therapeutic target for CNS injury/disease

April 10th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.